- 专利标题: Pemafibrate dosing regimens
-
申请号: US17708740申请日: 2022-03-30
-
公开(公告)号: US11554110B2公开(公告)日: 2023-01-17
- 发明人: Ryu Oshima , Masatoshi Ito , Chisato Nagai
- 申请人: Kowa Company, Ltd.
- 申请人地址: JP Chuo-ku
- 专利权人: Kowa Company, Ltd.
- 当前专利权人: Kowa Company, Ltd.
- 当前专利权人地址: JP Chuo-ku
- 代理商 Clark Sullivan
- 优先权: JP2017-128188 20170630
- 主分类号: A61K31/423
- IPC分类号: A61K31/423 ; A61K31/34 ; A61K31/4152 ; A61K31/427 ; A61K31/4353 ; A61K31/4402 ; A61K31/4433 ; A61K31/4709 ; A61K31/496 ; A61K31/513 ; A61K31/7034 ; A61K38/13 ; A61P3/06 ; A61K31/7048 ; A61K45/06
摘要:
To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy).
A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.
A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.
公开/授权文献
- US20220257627A1 Pemafibrate Dosing Regimens 公开/授权日:2022-08-18